

=> d his

(FILE 'HOME' ENTERED AT 10:50:52 ON 05 JAN 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 10:52:20 ON  
05 JAN 2005

E MASH D/CN  
E MASH DEBORAH/CN  
E MASH DEBORAH/AU

L1 179 S E3-E5

L2 119 DUP REM L1 (60 DUPLICATES REMOVED)

L3 21 S L2 AND (IBOGAINE OR NORIBOGAINE)

L4 1 S L3 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)

FILE 'FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2'  
ENTERED AT 11:00:03 ON 05 JAN 2005

E MASH DEBORAH/IN

L5 7 S E4-E5

L6 7 DUP REM L5 (0 DUPLICATES REMOVED)

L7 6 S L6 AND (IBOGAINE OR NORIBOGAINE)

L8 6 S L7 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?) *X not in absence  
of an operon anal*

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 11:09:01 ON  
05 JAN 2005

=> s 17 and (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)  
L8 6 L7 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)

=> d ibib 1-6

L8 ANSWER 1 OF 6

ACCESSION NUMBER:  
TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

PCTFULL COPYRIGHT 2005 Univentio on STN  
1999011250 PCTFULL ED 20020515

**NORIBOGAINE** IN THE TREATMENT OF **PAIN**  
AND DRUG ADDICTION

**NORIBOGAINE** UTILISEE POUR LE TRAITEMENT DE LA  
DOULEUR ET DE LA TOXICOMANIE

**MASH, Deborah, C.**  
NOVONEURON, INC.;

MASH, Deborah, C.  
English

Patent

*same invention*  
*in PCT*

NUMBER KIND DATE

-----

WO 9911250 A2 19990311

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU  
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH  
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT  
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF  
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
WO 1998-US18284 A 19980903  
US 1997-60/057,921 19970904

APPLICATION INFO.:

PRIORITY INFO.:

PCTFULL COPYRIGHT 2005 Univentio on STN  
1997020847 PCTFULL ED 20020514

**TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION**  
AND THEIR USE IN TREATING **SUBSTANCE ABUSE**  
**ANALOGUES D'IBOGAINE TRICYCLIQUES, LEUR**  
PREPARATION ET LEUR UTILISATION POUR TRAITER LA  
TOXICOMANIE

EFANGE, S., Mbua, Ngale;

**MASH, Deborah, Carmen**

REGENTS OF THE UNIVERSITY OF MINNESOTA;  
UNIVERSITY OF MIAMI

English

Patent

NUMBER KIND DATE

-----

WO 9720847 A1 19970612

CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE

WO 1996-US17868 A 19961106

US 1995-8/567,374 19951204

PCTFULL COPYRIGHT 2005 Univentio on STN  
1996003127 PCTFULL ED 20020514

A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND  
A COMPOSITION THEREFOR

PROCEDE ET COMPOSITION DE TRAITEMENT DE LA DEPENDANCE  
CHIMIQUE CHEZ LES MAMMIFERES

**MASH, Deborah, C.;**  
SANCHEZ-RAMOS, Juan;

HEARN, W., Lee

NDA INTERNATIONAL, INC.

English

Patent

NUMBER KIND DATE

*X*

WO 9603127 A1 19960208  
DESIGNATED STATES  
W: CA MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
APPLICATION INFO.: WO 1995-US9136 A 19950725  
PRIORITY INFO.: US 1994-280,187 19940725

L8 ANSWER 4 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2003:220261 USPATFULL  
TITLE: Method of treating chemical dependency in mammals and a composition therefor  
INVENTOR(S): **Mash, Deborah C.**, North Bay Village, FL, UNITED STATES  
Sanchez-Ramos, Juan, Tampa, FL, UNITED STATES  
Hearn, William Lee, Miami Springs, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153552	A1	20030814
APPLICATION INFO.:	US 2002-75915	A1	20020214 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MALIN HALEY AND DIMAGGIO, PA, 1936 S ANDREWS AVENUE, FORT LAUDERDALE, FL, 33316		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	386		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 5 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2002:34429 USPATFULL  
TITLE: Method of treating chemical dependency in mammals and a composition therefor  
INVENTOR(S): **Mash, Deborah C.**, 1501 NW. 9th Ave., Miami, FL, United States 33136  
Sanchez-Ramos, Juan, 1501 NW. 9th Ave., Miami, FL, United States 33136  
Hearn, W. Lee, 1 Bob Hope Rd., Miami, FL, United States 33136-1133

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6348456	B1	20020219
APPLICATION INFO.:	US 1996-727123		19961008 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-280187, filed on 25 Jul 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Malin, Haley & DiMaggio, P.A.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	387		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 6 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 97:27162 USPATFULL  
TITLE: Bioactive tricyclic **ibogaine** analogs  
INVENTOR(S): Efange, S. Mbua N., Plymouth, MN, United States  
**Mash, Deborah C.**, North Bay Village, FL, United States  
Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)  
University of Miami, Miami, FL, United States (U.S. corporation)

NUMBER            KIND            DATE

PATENT INFORMATION:            US 5616575            19970401  
APPLICATION INFO.:            US 1995-567374            19951204 (8)  
DOCUMENT TYPE:            Utility  
FILE SEGMENT:            Granted  
PRIMARY EXAMINER:            Reamer, James H.  
LEGAL REPRESENTATIVE:            Schwegman, Lundberg, Woessner & Kluth, P.A.  
NUMBER OF CLAIMS:            21  
EXEMPLARY CLAIM:            1,17  
NUMBER OF DRAWINGS:            10 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT:            671  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

X

=> s 12 and (ibogaine or noribogaine)  
L3 21 L2 AND (IBOGAINE OR NORIBOGAINE)

=> d ibib 1-21

L3 ANSWER 1 OF 21 MEDLINE on STN  
ACCESSION NUMBER: 2003102212 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12614886  
TITLE: **Ibogaine** analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes.  
AUTHOR: Passarella Daniele; Favia Raffaele; Giardini Alessandra; Lesma Giordano; Martinelli Marisa; Silvani Alessandra; Danieli Bruno; Efange Simon M N; **Mash Deborah C**  
CORPORATE SOURCE: Dipartimento di Chimica Organica e Industriale, Universita degli Studi di Milano, Via Venezian 21, 20133 Milan, Italy.. daniele.passarella@unimi.it  
SOURCE: Bioorganic & medicinal chemistry, (2003 Mar 20) 11 (6) 1007-14.  
PUB. COUNTRY: Journal code: 9413298. ISSN: 0968-0896.  
DOCUMENT TYPE: England: United Kingdom  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: English  
ENTRY MONTH: Priority Journals  
ENTRY DATE: 200311  
Entered STN: 20030305  
Last Updated on STN: 20031217  
Entered Medline: 20031124

L3 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:633279 CAPLUS  
DOCUMENT NUMBER: 139:159976  
TITLE: Composition and method using a **noribogaine** compound for treating chemical dependency in mammals  
INVENTOR(S): **Mash, Deborah C.**; Sanchez-Ramos, Juan; Hearn, William Lee  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 7 pp.  
DOCUMENT TYPE: CODEN: USXXCO  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: English  
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003153552	A1	20030814	US 2002-75915	20020214
PRIORITY APPLN. INFO.:			US 2002-75915	20020214
OTHER SOURCE(S):	MARPAT 139:159976			

L3 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:757619 CAPLUS  
DOCUMENT NUMBER: 136:111976  
TITLE: **Ibogaine** in the treatment of heroin withdrawal  
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Pablo, John; Tyndale, Rachel; Ervin, Frank R.; Kamlet, Jeffrey D.; Hearn, W. Lee  
CORPORATE SOURCE: Departments of Neurology and Pharmacology, University of Miami School of Medicine, Miami, FL, 33124, USA  
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine), 155-171  
PUBLISHER: CODEN: ALKAAR; ISSN: 0099-9598  
DOCUMENT TYPE: Academic Press  
LANGUAGE: Journal; General Review  
REFERENCE COUNT: English  
25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:757617 CAPLUS  
DOCUMENT NUMBER: 136:111974  
TITLE: Comparative neuropharmacology of **ibogaine**  
and its O-desmethyl metabolite, **noribogaine**  
AUTHOR(S): Baumann, Michael H.; Pablo, John; Ali, Syed F.;  
Rothman, Richard B.; **Mash, Deborah C.**  
CORPORATE SOURCE: Clinical Psychopharmacology Section Intramural  
Research Program National Institute on Drug Abuse,  
National Institutes of Health, Baltimore, MD, 21224,  
USA  
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine),  
79-113  
PUBLISHER: CODEN: ALKAAR; ISSN: 0099-9598  
Academic Press  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L3 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:321619 CAPLUS  
DOCUMENT NUMBER: 135:132300  
TITLE: In vivo neurobiological effects of **ibogaine**  
and its O-desmethyl metabolite, 12-hydroxyibogamine ( **noribogaine** ), in rats  
AUTHOR(S): Baumann, Michael H.; Rothman, Richard B.; Pablo, John  
P.; **Mash, Deborah C.**  
CORPORATE SOURCE: Clinical Psychopharmacology Section, Intramural  
Research Program, National Institute on Drug Abuse,  
National Institutes of Health, Baltimore, MD, USA  
SOURCE: Journal of Pharmacology and Experimental Therapeutics  
(2001), 297(2), 531-539  
PUBLISHER: CODEN: JPETAB; ISSN: 0022-3565  
American Society for Pharmacology and Experimental  
Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2000:842753 CAPLUS  
DOCUMENT NUMBER: 134:360947  
TITLE: **Ibogaine**: Complex pharmacokinetics, concerns  
for safety, and preliminary efficacy measures  
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Pablo,  
John; Tyndale, Rachel F.; Ervin, Frank D.; Williams,  
Izben C.; Singleton, Edward G.; Mayor, Manny  
CORPORATE SOURCE: Department of Neurology, University of Miami School of  
Medicine, Miami, FL, 33136, USA  
SOURCE: Annals of the New York Academy of Sciences (2000),  
914(Neurobiological Mechanisms of Drugs of Abuse),  
394-401  
PUBLISHER: CODEN: ANYAA9; ISSN: 0077-8923  
New York Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:410216 CAPLUS  
DOCUMENT NUMBER: 131:167751  
TITLE: Indole alkaloids from tissue-cultured *Tabernanthe*

AUTHOR(S) : iboga  
 Basile, Dominick V.; Punch, Michell S.; Pablo, John;  
 Brenner, Bruce; Hearn, W. Lee; **Mash, Deborah C.**  
 CORPORATE SOURCE: Department Biological Sciences, Lehman College, CUNY,  
 New York, NY, 10468, USA  
 SOURCE: Natural Product Letters (1999), 13 (3), 233-238  
 CODEN: NPLEEF; ISSN: 1057-5634  
 PUBLISHER: Harwood Academic Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1999:184122 CAPLUS  
 DOCUMENT NUMBER: 130:205166  
 TITLE: **Noribogaine** in the treatment of pain and  
 drug addiction  
 INVENTOR(S) : **Mash, Deborah C.**  
 PATENT ASSIGNEE(S) : Novoneuron, Inc., USA  
 SOURCE: PCT Int. Appl., 16 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911250	A2	19990311	WO 1998-US18284	19980903
WO 9911250	A3	19990805		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302754	AA	19990311	CA 1998-2302754	19980903
AU 9892174	A1	19990322	AU 1998-92174	19980903
AU 754088	B2	20021107		
EP 1009407	A2	20000621	EP 1998-944698	19980903
EP 1009407	B1	20040428		
EP 1327447	A1	20030716	EP 2003-75683	19980903
AT 265213	E	20040515	AT 1998-944698	19980903
PRIORITY APPLN. INFO.:			US 1997-57921P	P 19970904
			EP 1998-944698	A3 19980903
			WO 1998-US18284	W 19980903

L3 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:622200 CAPLUS  
 DOCUMENT NUMBER: 129:343618  
 TITLE: Modified **Ibogaine** Fragments: Synthesis and  
 Preliminary Pharmacological Characterization of  
 3-Ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5-  
 b]benzothiophenes  
 AUTHOR(S) : Efange, Simon M. N.; **Mash, Deborah C.**;  
 Khare, Anil B.; Ouyang, Quinjie  
 CORPORATE SOURCE: Departments of Radiology Medicinal Chemistry and  
 Neurosurgery, Graduate Program in Neuroscience  
 University of Minnesota, Minneapolis, MN, 55455, USA  
 SOURCE: Journal of Medicinal Chemistry (1998), 41(23),  
 4486-4491  
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 129:343618  
REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:540906 CAPLUS  
DOCUMENT NUMBER: 129:225279  
TITLE: Cytochrome P 450 2D6 catalyzes the O-demethylation of the psychoactive alkaloid **ibogaine** to 12-hydroxyibogamine  
AUTHOR(S): Obach, R. Scott; Pablo, John; **Mash, Deborah C.**  
CORPORATE SOURCE: Central Research Division, Department of Drug Metabolism, Groton, CT, 06340, USA  
SOURCE: Drug Metabolism and Disposition (1998), 26(8), 764-768  
PUBLISHER: Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:469623 CAPLUS  
DOCUMENT NUMBER: 129:170461  
TITLE: Medication development of **ibogaine** as a pharmacotherapy for drug dependence  
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Buck, Billy E.; Norenberg, Michael D.; Shapshak, Paul; Hearn, W. Lee; Sanchez-Ramos, Juan  
CORPORATE SOURCE: Departments of Neurology, Psychiatry, Orthopedics, and Pathology, University of Miami School of Medicine, Miami, FL, 33136, USA  
SOURCE: Annals of the New York Academy of Sciences (1998), 844(Neurochemistry of Drugs of Abuse), 274-292  
PUBLISHER: New York Academy of Sciences  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:108539 CAPLUS  
DOCUMENT NUMBER: 128:200970  
TITLE: **Noribogaine** stimulates naloxone-sensitive [<sup>35</sup>S]GTP $\gamma$ S binding  
AUTHOR(S): Pablo, John P.; **Mash, Deborah C.**  
CORPORATE SOURCE: Departments of Neurology (D4-5) and Molecular and Cellular Pharmacology, University of Miami School of Medicine, Miami, FL, USA  
SOURCE: NeuroReport (1998), 9(1), 109-114  
PUBLISHER: Rapid Science Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:231457 CAPLUS  
DOCUMENT NUMBER: 126:277643  
TITLE: Preparation of tricyclic **ibogaine** analogs for treating cocaine addiction  
INVENTOR(S): Efange, S. Mbua N.; **Mash, Deborah C.**  
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA;

SOURCE: University of Miami  
 U.S., 10 pp.  
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5616575	A	19970401	US 1995-567374	19951204
CA 2238524	AA	19970612	CA 1996-2238524	19961106
WO 9720847	A1	19970612	WO 1996-US17868	19961106
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 910567	A1	19990428	EP 1996-940321	19961106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 20000501702	T2	20000215	JP 1997-521270	19961106
PRIORITY APPLN. INFO.:			US 1995-567374	A 19951204
			WO 1996-US17868	W 19961106
OTHER SOURCE(S):	MARPAT 126:277643			

L3 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:572474 CAPLUS  
 DOCUMENT NUMBER: 125:238572  
 TITLE: Pharmacological screen for activities of  
 12-hydroxyibogamine: a primary metabolite of the  
 indole alkaloid **ibogaine**  
 AUTHOR(S): Staley, Julie K.; Ouyang, Qinjie; Pablo, John; Hearn,  
 W. Lee; Flynn, Donna D.; Rothman, Richard B.; Rice,  
 Kenner C.; **Mash, Deborah C.**  
 CORPORATE SOURCE: Dep. Neurol., Univ. Miami Sch. Med., Miami, FL, 33101,  
 USA  
 SOURCE: Psychopharmacology (Berlin) (1996), 127(1), 10-18  
 CODEN: PSCHDL; ISSN: 0033-3158  
 PUBLISHER: Springer  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

L3 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:321083 CAPLUS  
 DOCUMENT NUMBER: 124:333123  
 TITLE: **Noribogaine** compounds for treating chemical  
 dependency in mammals  
 INVENTOR(S): **Mash, Deborah C.**; Sanchez-Ramos, Juan;  
 Hearn, W. Lee  
 PATENT ASSIGNEE(S): Nda International, Inc., USA  
 SOURCE: PCT Int. Appl., 19 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603127	A1	19960208	WO 1995-US9136	19950725
W: CA, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9646132	A1	19960419	AU 1996-46132	19950725
EP 804200	A1	19971105	EP 1995-927295	19950725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
IL 114726	A1	20020421	IL 1995-114726	19950725
US 6348456	B1	20020219	US 1996-727123	19961008
PRIORITY APPLN. INFO.:			US 1994-280187	A 19940725
			WO 1995-US9136	W 19950725
OTHER SOURCE(S):	MARPAT 124:333123			

L3 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:850984 CAPLUS  
DOCUMENT NUMBER: 123:275065  
TITLE: Identification and quantification of **ibogaine** and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry  
AUTHOR(S): Hearn, William L.; Pablo, John; Hime, George W.; **Mash, Deborah C.**  
CORPORATE SOURCE: Metro-Dade County Medical Examiner's Dep., Univ. of Miami School of Medicine, Miami, FL, 33136, USA  
SOURCE: Journal of Analytical Toxicology (1995), 19(6), 427-34  
CODEN: JATOD3; ISSN: 0146-4760  
PUBLISHER: Preston Publications  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L3 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:621179 CAPLUS  
DOCUMENT NUMBER: 123:47718  
TITLE: Identification of a primary metabolite of **ibogaine** that targets serotonin transporters and elevates serotonin  
AUTHOR(S): **Mash, Deborah C.**; Staley, Julie K.; Baumann, Michael H.; Rothman, Richard B.; Hearn, W. Lee  
CORPORATE SOURCE: Dep. Neurology, Univ. Miami School Medicine, Miami, FL, 33136, USA  
SOURCE: Life Sciences (1995), 57(3), PL45-PL50  
CODEN: LIFSAK; ISSN: 0024-3205  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L3 ANSWER 18 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN  
ACCESSION NUMBER: 2002:197986 BIOSIS  
DOCUMENT NUMBER: PREV200200197986  
TITLE: Method of treating chemical dependency in mammals and a composition therefor.  
AUTHOR(S): **Mash, Deborah C.** [Inventor, Reprint author]; Sanchez-Ramos, Juan [Inventor]; Hearn, W. Lee [Inventor]  
CORPORATE SOURCE: 1501 NW. 9th Ave., Miami, FL, 33136, USA  
PATENT INFORMATION: US 6348456 February 19, 2002  
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 19, 2002) Vol. 1255, No. 3.  
<http://www.uspto.gov/web/menu/patdata.html>. e-file.  
CODEN: OGUPE7. ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
ENTRY DATE: Entered STN: 13 Mar 2002  
Last Updated on STN: 13 Mar 2002

L3 ANSWER 19 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN  
ACCESSION NUMBER: 2001:205680 BIOSIS  
DOCUMENT NUMBER: PREV200100205680  
TITLE: **Ibogaine**: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.  
AUTHOR(S): **Mash, Deborah C.** [Reprint author]; Kovera, Craig A.; Pablo, John; Tyndale, Rachel F.; Ervin, Frank D.; Williams, Izben C.; Singleton, Edward G.; Mayor, Manny  
CORPORATE SOURCE: Department of Neurology (D4-5), 1501 N. W. 9th Avenue, Miami, FL, USA  
dmash@med.miami.edu  
SOURCE: Ali, Syed F. Ann. N. Y. Acad. Sci., (2000) pp. 394-401.  
Annals of the New York Academy of Sciences. Neurobiological mechanisms of drugs and abuse: Cocaine, ibogaine, and

substituted amphetamines. print.  
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.  
Meeting Info.: Conference on Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine and Substituted Amphetamines held at a Satellite Meeting of the International Society for Neurochemistry and the European Society for Neurochemistry. Copenhagen, Denmark. August 04-06, 1999.  
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 1-57331-279-7 (cloth), 1-57331-280-0 (paper).

DOCUMENT TYPE: Book

Conference; (Meeting)

Book; (Book Chapter)

Conference; (Meeting Paper)

LANGUAGE: English

ENTRY DATE: Entered STN: 25 Apr 2001

Last Updated on STN: 19 Feb 2002

L3 ANSWER 20 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

ACCESSION NUMBER: 1998:383618 BIOSIS

DOCUMENT NUMBER: PREV199800383618

TITLE: Medication development of **ibogaine** as a pharmacotherapy for drug dependence.

AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Buck, Billy E.; Norenberg, Michael D.; Shapshak, Paul; Hearn, W. Lee; Sanchez-Ramos, Juan

CORPORATE SOURCE: Dep. Neurol., 1501 N.W. 9th Ave., Miami, FL 33136, USA  
SOURCE: Ali, S. F. [Editor]. Ann. N. Y. Acad. Sci., (1998) pp.

274-292. Annals of the New York Academy of Sciences; The neurochemistry of drugs of abuse; Cocaine, ibogaine, and substituted amphetamines. print.

Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, New York 10021, USA. Series: Annals of the New York Academy of Sciences.

Meeting Info.: Satellite Meeting of the International Society for Neurochemistry and the American Society for Neurochemistry. Hamilton, Bermuda. July 16-18, 1997.

American Society for Neurochemistry; International Society for Neurochemistry.

CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 1-57331-145-6 (cloth), 1-57331-146-4 (paper).

DOCUMENT TYPE: Book

Conference; (Meeting)

Book; (Book Chapter)

Conference; (Meeting Paper)

LANGUAGE: English

ENTRY DATE: Entered STN: 2 Sep 1998

Last Updated on STN: 2 Sep 1998

L3 ANSWER 21 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

ACCESSION NUMBER: 1996:142587 BIOSIS

DOCUMENT NUMBER: PREV199698714722

TITLE: Neuropsychiatric effects of **ibogaine** in drug dependent patients.

AUTHOR(S): Douyon, Richard; Levin, Bonnie; Hearn, W. Lee; Sanchez-Ramos, Juan; **Mash, Deborah C.**

CORPORATE SOURCE: Univ. Miami Sch. Med., Miami, FL, USA

SOURCE: Psychopharmacology Bulletin, (1995) Vol. 31, No. 3, pp. 561.

Meeting Info.: New Clinical Drug Evaluation Unit Meeting. May-June 1995.

CODEN: PSYBB9. ISSN: 0048-5764.

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

DOCUMENT TYPE:

LANGUAGE: Conference; (Meeting Poster)  
ENTRY DATE: English  
Entered STN: 3 Apr 1996  
Last Updated on STN: 26 Apr 1996

L3 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:850984 CAPLUS

DOCUMENT NUMBER: 123:275065

TITLE: Identification and quantification of **ibogaine** and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry

AUTHOR(S): Hearn, William L.; Pablo, John; Hime, George W.; **Mash, Deborah C.**

CORPORATE SOURCE: Metro-Dade County Medical Examiner's Dep., Univ. of Miami School of Medicine, Miami, FL, 33136, USA

SOURCE: Journal of Analytical Toxicology (1995), 19(6), 427-34  
CODEN: JATOD3; ISSN: 0146-4760

PUBLISHER: Preston Publications

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This report describes a sensitive method for quantitating **ibogaine** and a single major metabolite in biol. fluids and brain tissue. We identified the metabolite as 12-hydroxy-ibogamine (12-OH-ibogamine or **noribogaine**) by full-scan, electron-impact gas chromatog.-mass spectrometry (GC-MS). **Ibogaine**, 12-OH-ibogamine, and o-(methyl)-**ibogaine-d3** (**ibogaine-d3**) internal standard were isolated by solvent extraction under basic conditions. The resulting organic extract was evaporated to dryness, and the residue was derivatized at room temperature with Et iodide in the presence of tri-Me anilinium hydroxide in DMSO. The reaction was terminated by acidification and washed with organic solvents to remove impurities. The aqueous phase was then alkalinized and reextd. The organic extract was concentrated and analyzed by GC-MS. Quantitation was based upon the ratios of the mol. ions at m/z 310 for **ibogaine**, m/z 313 for **ibogaine-d3**, and m/z 324 for 12-OH-ibogamine Et ether. The limit of detection was 5 ng/mL for both **ibogaine** and derivatized 12-OH-ibogamine, and limits of quantitation were between 5 and 10 ng/mL for all matrixes tested. Calibration curves were linear in the range of 5-1000 ng/mL or ng/g for both analytes.

=> d his

(FILE 'HOME' ENTERED AT 14:06:12 ON 04 JAN 2005)

FILE 'REGISTRY' ENTERED AT 14:07:02 ON 04 JAN 2005  
E IBOGAIN/CN

L1 1 S E3


FILE 'CAPLUS' ENTERED AT 14:14:38 ON 04 JAN 2005

L2 454 S L1 OR NSC(W)249764 OR ?IBOGAINE OR IBOGAIN  
L3 15 S L2(L) (PAIN OR MIGRAINE OR HEADACHE OR ANALGE?)  
Q *NO PAIN*

FILE 'FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2'  
ENTERED AT 14:48:31 ON 04 JAN 2005

L4 97 S L3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Ibogamine, 12-methoxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamine deriv.

CN Ibogaine (7CI, 8CI)

OTHER NAMES:

CN (-)-Ibogaine

CN Ibogain

CN NSC 249764

=> s e4


L1

1 NORIBOGAINE/CN

=> d rn str cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 481-88-9 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Ibogamin-12-ol (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamin-12-ol deriv.

CN Ibogaine, O-demethyl- (6CI, 7CI, 8CI)

OTHER NAMES:

CN 12-Hydroxyibogamine

CN **Noribogaine**

CN O-Demethylibogaine

CN O-Noribogaine

L4 ANSWER 30 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1997029735 PCTFULL ED 20020514  
TITLE (ENGLISH): DERMAL PENETRATION ENHancers AND DRUG DELIVERY SYSTEMS  
INVOLVING SAME  
TITLE (FRENCH): PROMOTEURS DE PENETRATION DERMIQUE ET SYSTEME  
D'ADMINISTRATION DE MEDICAMENTS COMPRENANT CES  
PROMOTEURS  
INVENTOR(S): REED, Barry, Leonard;  
MORGAN, Timothy, Matthias;  
FINNIN, Barrie, Charles  
MONASH UNIVERSITY;  
REED, Barry, Leonard;  
MORGAN, Timothy, Matthias;  
FINNIN, Barrie, Charles  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9729735	A1	19970821

## DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT  
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI  
SK TJ TM TR TT UA UG US UZ VN YU KE LS MW SD SZ UG AM  
AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR  
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE  
SN TD TG

APPLICATION INFO.: WO 1997-AU91 A 19970219  
PRIORITY INFO.: AU 1996-PN 8144 19960219

L4 ANSWER 31 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1997020847 PCTFULL ED 20020514

TITLE (ENGLISH): TRICYCLIC **IBOGAINE** ANALOGS, THEIR PREPARATION  
AND THEIR USE IN TREATING SUBSTANCE ABUSE  
TITLE (FRENCH): ANALOGUES D'**IBOGAINE** TRICYCLIQUES, LEUR  
PREPARATION ET LEUR UTILISATION POUR TRAITER LA  
TOXICOMANIE

INVENTOR(S): EFANGE, S., Mbua, Ngale;  
MASH, Deborah, Carmen  
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF MINNESOTA;  
UNIVERSITY OF MIAMI

LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent

NUMBER	KIND	DATE
WO 9720847	A1	19970612

## DESIGNATED STATES

W:

APPLICATION INFO.: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE  
PRIORITY INFO.: WO 1996-US17868 A 19961106  
US 1995-8/567,374 19951204

L4 ANSWER 32 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1996003127 PCTFULL ED 20020514

TITLE (ENGLISH): A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND  
A COMPOSITION THEREFOR  
TITLE (FRENCH): PROCEDE ET COMPOSITION DE TRAITEMENT DE LA DEPENDANCE  
CHIMIQUE CHEZ LES MAMMIFERES

INVENTOR(S): MASH, Deborah, C.;  
SANCHEZ-RAMOS, Juan;  
HEARN, W., Lee  
PATENT ASSIGNEE(S): NDA INTERNATIONAL, INC.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER KIND DATE *X*  
-----  
WO 9603127 A1 19960208

## DESIGNATED STATES

W:

APPLICATION INFO.:

PRIORITY INFO.:

CA MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
WO 1995-US9136 A 19950725  
US 1994-280,187 19940725

L4 ANSWER 33 OF 97

PCTFULL COPYRIGHT 2005 Univentio on STN

1991018609 PCTFULL ED 20020513

ACCESSION NUMBER:

A RAPID METHOD FOR INTERRUPTING OR ATTENUATING

TITLE (ENGLISH):

POLY-DRUG DEPENDENCY SYNDROMES

TITLE (FRENCH):

PROCEDE RAPIDE D'INTERRUPTION OU D'ATTENUATION DES  
SYNDROMES DE DEPENDANCE POLYDROGUES

INVENTOR(S):

LOTSOF, Howard, S.

PATENT ASSIGNEE(S):

NDA INTERNATIONAL, INC.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER KIND DATE

-----

WO 9118609 A1 19911212

## DESIGNATED STATES

W:

AT BE CA CH DE DK ES FR GB GR IT JP LU NL SE

WO 1991-US3781 A 19910530

US 1990-531,100 19900531

L4 ANSWER 34 OF 97

PCTFULL COPYRIGHT 2005 Univentio on STN

1985002115 PCTFULL ED 20020507

ACCESSION NUMBER:

A RAPID METHOD FOR INTERRUPTING THE NARCOTIC ADDICTION  
SYNDROME

TITLE (ENGLISH):

METHODE RAPIDE PERMETTANT D'INTERROMPRE LE SYNDROME  
D'ACCOUTUMANCE AUX NARCOTIQUES

INVENTOR(S):

LOTSOF, Howard, S.

PATENT ASSIGNEE(S):

LOTSOF, Howard, S.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER KIND DATE

-----

WO 8502115 A1 19850523

## DESIGNATED STATES

W:

AT AU BE CF CG CH CM DE DK FI FR GA GB JP LU ML MR NL  
SE SN TD TG

WO 1984-US1851 A 19841113

US 1983-553,138 19831118

APPLICATION INFO.:

PRIORITY INFO.:

L4 ANSWER 78 OF 97 USPATFULL on STN  
 ACCESSION NUMBER: 1999:117490 USPATFULL  
 TITLE: Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration  
 INVENTOR(S): Olney, John W., Ladue, MO, United States  
 PATENT ASSIGNEE(S): Farber, Nuri B., University City, MO, United States  
 Washington University, St. Louis, MO, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5958919		19990928
APPLICATION INFO.:	US 1996-710727		19960920 (8)
DOCUMENT TYPE:		Utility	
FILE SEGMENT:		Granted	
PRIMARY EXAMINER:		Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:		Kelly, Patrick D.	
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2	Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	3890		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L4 ANSWER 79 OF 97 USPATFULL on STN  
 ACCESSION NUMBER: 1999:81826 USPATFULL  
 TITLE: Use of **ibogaine** for treating neuropathic pain  
 INVENTOR(S): Olney, John W., Ladue, MO, United States  
 PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925634		19990720
APPLICATION INFO.:	US 1997-854979		19970513 (8)
RELATED APPLN. INFO.:		Division of Ser. No. US 1995-398731, filed on 6 Mar 1995, now patented, Pat. No. US 5629307, issued on 13 May 1997 which is a continuation-in-part of Ser. No. US 1992-877839, filed on 1 May 1992 which is a continuation-in-part of Ser. No. US 1990-467139, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-424548, filed on 20 Oct 1989, now patented, Pat. No. US 5034400	
DOCUMENT TYPE:		Utility	
FILE SEGMENT:		Granted	
PRIMARY EXAMINER:		Weddington, Kevin E.	
LEGAL REPRESENTATIVE:		Kelly, Patrick D.	
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1	Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1254		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L4 ANSWER 80 OF 97 USPATFULL on STN  
 ACCESSION NUMBER: 1999:56487 USPATFULL  
 TITLE: Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction  
 INVENTOR(S): Olney, John W., Ladue, MO, United States  
 PATENT ASSIGNEE(S): Farber, Nuri B., University City, MO, United States  
 Washington University, St. Louis, MO, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5902815		19990511
APPLICATION INFO.:	US 1996-709222		19960903 (8)
DOCUMENT TYPE:		Utility	

FILE SEGMENT: Granted  
PRIMARY EXAMINER: MacMillan, Keith D.  
LEGAL REPRESENTATIVE: Kelly, Patrick D.  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 2014  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 1999:27632 USPATFULL  
TITLE: Preventing neuronal degeneration in Alzheimer's disease  
INVENTOR(S): Olney, John W., Ladue, MO, United States  
PATENT ASSIGNEE(S): Farber, Nuri B., University City, MO, United States  
Washington University, St. Louis, MO, United States  
(U.S. corporation)

NUMBER	KIND	DATE
US 5877173		19990302
US 1996-704093		19960828 (8)

PATENT INFORMATION:  
APPLICATION INFO.:  
DOCUMENT TYPE:  
FILE SEGMENT:  
PRIMARY EXAMINER:  
LEGAL REPRESENTATIVE:  
NUMBER OF CLAIMS:  
EXEMPLARY CLAIM:  
NUMBER OF DRAWINGS:  
LINE COUNT:  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 1998:98932 USPATFULL  
TITLE: DHA-pharmaceutical agent conjugates of taxanes  
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
Swindell, Charles S., Merion, PA, United States  
Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

NUMBER	KIND	DATE
US 5795909		19980818
US 1996-651312		19960522 (8)

PATENT INFORMATION:  
APPLICATION INFO.:  
DOCUMENT TYPE:  
FILE SEGMENT:  
PRIMARY EXAMINER:  
LEGAL REPRESENTATIVE:  
NUMBER OF CLAIMS:  
EXEMPLARY CLAIM:  
NUMBER OF DRAWINGS:  
LINE COUNT:  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 1998:69048 USPATFULL  
TITLE: Use of kainic acid antagonists to prevent toxic side  
effects of NMDA antagonists  
INVENTOR(S): Olney, John W., 1 Lorenzo La., St. Louis, MO, United  
States 63124

NUMBER	KIND	DATE
US 5767130		19980616
US 1995-407068		19950320 (8)

PATENT INFORMATION:  
APPLICATION INFO.:  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-877839, filed  
on 1 May 1992 which is a continuation-in-part of Ser.

No. US 1990-467139, filed on 18 Jan 1990, now abandoned  
which is a continuation-in-part of Ser. No. US  
1989-424548, filed on 20 Oct 1989, now patented, Pat.  
No. US 5034400

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Weddington, Kevin E.  
LEGAL REPRESENTATIVE: Kelly, Patrick D.  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 1795  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 97:40786 USPATFULL  
TITLE: Use of ibogaine in reducing excitotoxic brain damage  
INVENTOR(S): Olney, John W., 1 Lorenzo La., St. Louis, MO, United  
States 63124

NUMBER	KIND	DATE
US 5629307		19970513
US 1995-398731		19950306 (8)
Continuation-in-part of Ser. No. US 1992-877839, filed on 1 May 1992 which is a continuation-in-part of Ser. No. US 1990-467139, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-424548, filed on 20 Oct 1989, now patented, Pat. No. US 5034400		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Weddington, Kevin E.  
LEGAL REPRESENTATIVE: Kelly, Patrick D.  
NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 1250  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 97:27162 USPATFULL  
TITLE: Bioactive tricyclic ibogaine analogs  
INVENTOR(S): Efange, S. Mbua N., Plymouth, MN, United States  
Mash, Deborah C., North Bay Village, FL, United States  
Regents of the University of Minnesota, Minneapolis,  
MN, United States (U.S. corporation)  
University of Miami, Miami, FL, United States (U.S.  
corporation)

NUMBER	KIND	DATE
US 5616575		19970401
US 1995-567374		19951204 (8)

PATENT INFORMATION: WO97/2847  
APPLICATION INFO.:  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Reamer, James H.  
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1,17  
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 671  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 97:16066 USPATFULL  
TITLE: Use of alpha-2 adrenergic drugs to prevent adverse  
effects of NMDA receptor hypofunction (NRH)

INVENTOR(S) : Olney, John W., Ladue, MO, United States  
PATENT ASSIGNEE(S) : Farber, Nuri B., University City, MO, United States  
Washington University, St. Louis, MO, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5605911		19970225
APPLICATION INFO.:	US 1995-381334		19950131 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Kelly, Patrick D.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1935		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L4 ANSWER 87 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 92:82575 USPATFULL  
TITLE: Rapid method for interrupting or attenuating poly-drug dependency syndromes  
INVENTOR(S) : Lotsof, Howard S., 46 Oxford Pl., Staten Island, NY, United States 10301

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5152994		19921006
APPLICATION INFO.:	US 1990-531100		19900531 (7)
DISCLAIMER DATE:	20020212		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Miskin, Howard C.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	292		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L4 ANSWER 88 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 91:50468 USPATFULL  
TITLE: Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome  
INVENTOR(S) : Lotsof, Howard S., Staten Island, NY, United States  
PATENT ASSIGNEE(S) : NDA International, Inc., Staten Island, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5026697		19910625
APPLICATION INFO.:	US 1990-530263		19900530 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Friedman, Stanley J.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	234		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L4 ANSWER 89 OF 97 USPATFULL on STN  
ACCESSION NUMBER: 89:67469 USPATFULL  
TITLE: Rapid method for attenuating the alcohol dependency syndrome  
INVENTOR(S) : Lotsof, Howard S., Staten Island, NY, United States  
PATENT ASSIGNEE(S) : NDA International, Inc., Staten Island, NY, United States (U.S. corporation)

NUMBER            KIND            DATE

PATENT INFORMATION:            US 4857523            19890815  
APPLICATION INFO.:            US 1988-221030            19880718 (7)  
DOCUMENT TYPE:            Utility  
FILE SEGMENT:            Granted  
PRIMARY EXAMINER:            Friedman, Stanley J.  
LEGAL REPRESENTATIVE:            Miskin, Howard C.  
NUMBER OF CLAIMS:            9  
EXEMPLARY CLAIM:            1  
LINE COUNT:            326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 97 USPATFULL on STN

ACCESSION NUMBER:            86:26606 USPATFULL  
TITLE:            Rapid method for interrupting the cocaine and  
                  amphetamine abuse syndrome  
INVENTOR(S):            Lotsof, Howard S., 330 Stanley Ave., Staten Island, NY,  
                  United States 10301

NUMBER            KIND            DATE

PATENT INFORMATION:            US 4587243            19860506  
APPLICATION INFO.:            US 1985-754836            19850715 (6)  
DOCUMENT TYPE:            Utility  
FILE SEGMENT:            Granted  
PRIMARY EXAMINER:            Friedman, Stanley J.  
LEGAL REPRESENTATIVE:            Miskin, Howard C.  
NUMBER OF CLAIMS:            9  
EXEMPLARY CLAIM:            1  
LINE COUNT:            289  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 97 USPATFULL on STN

ACCESSION NUMBER:            85:8978 USPATFULL  
TITLE:            Rapid method for interrupting the narcotic addiction  
                  syndrome  
INVENTOR(S):            Lotsof, Howard S., 330 Stanley Ave., Staten Island, NY,  
                  United States 10301

NUMBER            KIND            DATE

PATENT INFORMATION:            US 4499096            19850212  
APPLICATION INFO.:            US 1983-553138            19831118 (6)  
DOCUMENT TYPE:            Utility  
FILE SEGMENT:            Granted  
PRIMARY EXAMINER:            Friedman, Stanley J.  
LEGAL REPRESENTATIVE:            Miskin, Howard C.  
NUMBER OF CLAIMS:            11  
EXEMPLARY CLAIM:            1  
LINE COUNT:            302  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 1-15

L3 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:836575 CAPLUS  
DOCUMENT NUMBER: 139:341734  
TITLE: Compositions of  $\alpha 3\beta 4$  nicotinic receptor antagonists and opioid agonist analgesics for pain relieving and diarrhea  
INVENTOR(S): Simon, David Lew  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 12 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003199439	A1	20031023	US 2002-127359	20020422
US 2003199496	A1	20031023	US 2002-186402	20020701
WO 2003088918	A2	20031030	WO 2003-US12333	20030422
WO 2003088918	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-127359 A2 20020422  
US 2002-186402 A 20020701

AB Disclosed is a pharmaceutical composition comprising an opioid agonist analgesic and an  $\alpha 3\beta 4$  nicotinic receptor antagonist effective to sep. the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist. For example, morphine was formulated with 18-methoxy coronaridine for pain relief.

L3 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:757622 CAPLUS  
DOCUMENT NUMBER: 136:111979  
TITLE: Modulation of the effects of rewarding drugs by ibogaine  
AUTHOR(S): Parker, Linda A.; Siegel, Shepard  
CORPORATE SOURCE: Department of Psychology, Wilfrid Laurier University, Waterloo, ON, N2L 3C5, Can.  
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine), 211-225  
PUBLISHER: Academic Press  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
AB A review describes evidence that **ibogaine** modulates the drug effects in animals. Exptl. results show that **ibogaine** modulates various opiate effects in rats, as well as potentiates opiate-induced analgesia and lethality and interferes with morphine tolerance. When assessed in self-administration and in place preference learning, **ibogaine** modulates the rewarding properties of stimulants and interferes with the rewarding properties of morphine. (c) 2001 Academic Press.  
REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:184122 CAPLUS

DOCUMENT NUMBER: 130:205166  
TITLE: **Noribogaine** in the treatment of **pain**  
and drug addiction  
INVENTOR(S): Mash, Deborah C.  
PATENT ASSIGNEE(S): Novoneuron, Inc., USA  
SOURCE: PCT Int. Appl., 16 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1

*Own PCT*

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911250	A2	19990311	WO 1998-US18284	19980903
WO 9911250	A3	19990805		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302754	AA	19990311	CA 1998-2302754	19980903
AU 9892174	A1	19990322	AU 1998-92174	19980903
AU 754088	B2	20021107		
EP 1009407	A2	20000621	EP 1998-944698	19980903
EP 1009407	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
EP 1327447	A1	20030716	EP 2003-75683	19980903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 265213	E	20040515	AT 1998-944698	19980903
			US 1997-57921P	P 19970904
			EP 1998-944698	A3 19980903
			WO 1998-US18284	W 19980903
PRIORITY APPLN. INFO.:				

AB The present invention is directed to methods of treating patients for **pain** by administering **noribogaine**. **Noribogaine** may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the **noribogaine** treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

L3 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:656503 CAPLUS

DOCUMENT NUMBER: 129:270563

TITLE: Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice

AUTHOR(S): Sharma, Shyam Sunder; Bhargava, Hemendra N.

CORPORATE SOURCE: Department Pharmaceutics Pharmacodynamics (M/C 865), Health Sciences Center, University Illinois, Chicago, IL, 60612, USA

SOURCE: Pharmacology (1998), 57(5), 229-232

CODEN: PHMGBN; ISSN: 0031-7012

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, and noribogaine, a metabolite of ibogaine, on morphine antinociception were determined in male Swiss-Webster mice. Mice were rendered tolerant to morphine by implanting them with a pellet containing 25 mg of morphine base for 3 days. Placebo pellet-implanted mice served as controls. The antinociception of morphine (10 mg/kg, s.c.) was determined alone or in combination with an appropriate dose of ibogaine or noribogaine. Tolerance to morphine developed as a result of morphine pellet implantation as evidenced by decreased antinociceptive response to morphine. Both ibogaine and noribogaine dose-dependently enhanced morphine antinociception in morphine-tolerant but not in morphine-naive

mice. It is concluded that ibogaine and noribogaine enhance morphine antinociception in morphine-tolerant mice.

L3 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:478266 CAPLUS

DOCUMENT NUMBER: 129:225605

TITLE: Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release

AUTHOR(S): Sershen, Henry; Hashim, Audrey; Lajtha, Abel

CORPORATE SOURCE: Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, 10962, USA

SOURCE: Brain Research (1998), 801(1-2), 67-71

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB It has been reported that kappa-opioids produce greater **analgesia** in women than in men. Sex differences are also apparent in drug-induced behaviors. Repeated administration of cocaine (25 mg/kg) produced a greater locomotor and sensitization response in C57BL/6By female mice. It was examined whether the increased sensitization in females to repeated cocaine administration was related to differences in kappa-opioid responses. The effects of the kappa agonist U62066 (spiradoline mesylate) on cocaine-induced locomotor stimulation in vivo and NMDA-mediated dopamine release in vitro were measured. In male, but not female mice, U62066 (1 mg/kg) given 30 min before cocaine potentiated the locomotor stimulation of an acute cocaine administration. U-62066 did not affect the development of locomotor sensitization with repeated cocaine administration (25 mg/kg s.c., once daily for 3 days), and a further enhanced response was not seen on days 2 and 3. It was then examined whether dopamine release, measured in vitro, plays a role in sex dependent differences in kappa-opioid- or NMDA-modulated dopaminergic function. In tissue perfusion studies, the in vitro NMDA (25  $\mu$ M)-evoked release of labeled dopamine from striatum was lower in females (fractional release=5.4 $\pm$ 0.4 and 4.0 $\pm$ 0.4 in male and female mouse striatum). U62066 (1  $\mu$ M) and **ibogaine** (1  $\mu$ M), an indole alkaloid claimed to be useful in the treatment of drug addiction that acts in part at the kappa-opioid receptor, both reduced the NMDA (25  $\mu$ M)-evoked release of dopamine. Inhibition of the release was significantly greater in tissue from male mice. Prior in vivo cocaine administration did not alter the NMDA-evoked dopamine release. Our studies indicate that kappa-opioid and NMDA receptor activity show differences between female and male mice that may account for differences in cocaine-induced behaviors, but do not exclude the role of other heteroceptors modulating dopamine release.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:679297 CAPLUS

DOCUMENT NUMBER: 128:266

TITLE: Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice

AUTHOR(S): Bhargava, Hemendra N.; Cao, Ying-Jun

CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (m/c 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, IL, 60612, USA

SOURCE: Brain Research (1997), 771(2), 343-346

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of noribogaine, a metabolite of ibogaine, on the development of tolerance to the antinociception action of morphine was determined in male Swiss-Webster mice. Ibogaine is an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga. Morphine tolerance in mice was

developed by two different methods. Mice were rendered tolerant to morphine either by s.c. implantation of a pellet containing 25 mg morphine free base for 4 days or by injecting morphine (20 mg/kg, s.c.) twice a day for 4 days. Placebo pellet implanted mice or vehicle injected mice served as controls. To determine the effect of i.p. administered noribogaine on tolerance development, the drug was injected in the appropriate dose twice a day. In pellet implanted mice, a dose of 20 mg/kg of noribogaine attenuated the tolerance to morphine whereas lower doses had no effect. Similarly, in mice given multiple injections of morphine, noribogaine attenuated tolerance development at 20 and 40 mg/kg doses. Previous studies from this laboratory had shown that ibogaine at 40 and 80 mg/kg doses inhibited tolerance to morphine. Because noribogaine could attenuate morphine tolerance at lower doses than ibogaine, it is concluded that the attenuating effect of ibogaine on morphine tolerance may be mediated by its conversion to noribogaine, a more active metabolite.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:156629 CAPLUS

DOCUMENT NUMBER: 126:258958

TITLE: Effects of ibogaine on the development of tolerance to antinociceptive action of  $\mu$ -,  $\delta$ - and  $\kappa$ -opioid receptor agonists in mice

AUTHOR(S): Cao, Ying-Jun; Bhargava, Hemendra N.

CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (m/c 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, USA

SOURCE: Brain Research (1997), 752(1,2), 250-254

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of ibogaine, an alkaloid isolated from the bark of the African shrub, *Tabernanthe iboga*, on the development of tolerance to the antinociception action of morphine, U-50,488H and [D-Pen<sub>2</sub>,D-Pen<sub>5</sub>]enkephalin (DPDPE), which are  $\mu$ -,  $\kappa$ - and  $\delta$ -opioid receptor agonists, resp., were determined in male Swiss-Webster mice. Mice were rendered tolerant to opioid receptor agonists by injecting morphine (20 mg/kg, s.c.), U-50,488H (25 mg/kg, i.p.) or DPDPE (20  $\mu$ g/mouse, i.c.v.) twice a day for 4 days. Ibogaine (20, 40 or 80 mg/kg, i.p.) given twice a day for 4 days did not alter the tail-flick latency. Ibogaine (40 or 80 mg/kg, i.p.) injected 10 min before each injection of morphine inhibited the development of tolerance to the antinociceptive action of morphine, however, the lower dose of ibogaine (20 mg/kg, i.p.) was ineffective. Ibogaine (20, 40 or 80 mg/kg, i.p.) given prior to the injection of U-50,488H or DPDPE did not modify the development of tolerance to their antinociceptive action. It is concluded that ibogaine inhibits selectively the development of tolerance to the antinociceptive action of  $\mu$ - but not  $\kappa$ - or  $\delta$ -opioid receptor agonists in mice.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:156627 CAPLUS

DOCUMENT NUMBER: 126:246705

TITLE: Effects of ibogaine and noribogaine on the antinociceptive action of  $\mu$ -,  $\delta$ - and  $\kappa$ -opioid receptor agonists in mice

AUTHOR(S): Bhargava, Hemendra N.; Cao, Ying-Jun; Zhao, Guo-Min

CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (M/C 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, USA

SOURCE: Brain Research (1997), 752(1,2), 234-238

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, has been claimed to decrease the self-administration of drugs of abuse like morphine, cocaine and alc. To determine whether these effects are mediated via opioid receptor systems, the effects of ibogaine and its metabolite, noribogaine on the antinociceptive actions of morphine, U-50,488H and [D-Pen2,D-Pen5]enkephalin (DPDPE) which are  $\mu$ - $\kappa$ - and  $\delta$ -opioid receptor agonists, resp., were determined in male Swiss-Webster mice. Administration of morphine (7 or 10 mg/kg, s.c.), U-50,488H (15 or 25 mg/kg, i.p.) or DPDPE (10  $\mu$ g/mouse, i.c.v.) produced antinociception in mice as measured by the tail-flick test. Ibogaine (10, 20 or 40 mg/kg, i.p.) by itself did not alter the tail-flick latency. The same doses of ibogaine injected 10 min before the opioid drugs did not modify the antinociceptive actions of morphine, U-50,488H or DPDPE. Ibogaine administered 4 h or 24 h prior to morphine injection did not modify the antinociceptive action of the latter. A dose of 40 mg/kg (i.p.) of noribogaine enhanced the antinociceptive activity of morphine (10 mg/kg, s.c.). Similarly, the doses of 40 and 80 mg/kg of noribogaine enhanced the antinociception produced by a smaller dose of morphine (5 mg/kg, s.c.). However, antinociception induced by U-50,488H and DPDPE was not modified by noribogaine (10-40 mg/kg). It is concluded that ibogaine, which has been suggested to decrease the self-administration of cocaine and opiates like heroin in humans, does not produce such an action by interacting directly with multiple opioid receptors. However, the metabolite of ibogaine enhances the antinociception of morphine but not of U-50,488H or DPDPE. Thus, in vivo evidence has been provided for the possible interaction of ibogaine with  $\mu$ -opioid receptor following its metabolism to noribogaine.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:692751 CAPLUS

DOCUMENT NUMBER: 126:26668

TITLE: Modulation of morphine-induced antinociception by ibogaine and noribogaine

AUTHOR(S): Bagal, A. A.; Hough, L. B.; Nalwalk, J. W.; Glick, S. D.

CORPORATE SOURCE: Department of Pharmacology and Neuroscience, A-136, Albany Medical College, 47 New Scotland Ave., Albany, NY, 12208, USA

SOURCE: Brain Research (1996), 741(1,2), 258-262  
CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The potential modulation of morphine antinociception by the putative anti-addictive agent ibogaine and its active metabolite (noribogaine) was investigated in rats with the radiant heat tail-flick test. Ibogaine pretreatment (40 mg/kg, i.p., 19 h) significantly decreased morphine (4 mg/kg, s.c.) antinociception, with no effects in the absence of morphine. However, co-administration of ibogaine (1-40 mg/kg, i.p.) and morphine (4 mg/kg, s.c.) exhibited a dose-dependent enhancement of morphine antinociception. Co-administration of noribogaine (40 mg/kg, i.p.) and morphine also resulted in an increase in morphine antinociception, while noribogaine pretreatment (19 h) had no effect on morphine antinociception. The results show that ibogaine acutely potentiates morphine antinociception and that noribogaine could be the active metabolite responsible for this effect. However, the inhibitory effects of a 19 h ibogaine pretreatment, which resemble ibogaine-induced inhibition of morphine's stimulant properties, cannot be accounted for by noribogaine.

L3 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:587657 CAPLUS

DOCUMENT NUMBER: 125:238454

TITLE: Effect of ibogaine on the development of tolerance to the analgesic effect of morphine

AUTHOR(S) : Siegel, Shepard; Kim, Joseph A.; Weise-Kelly, Lorraine; Parker, Linda A.  
CORPORATE SOURCE: Department Psychology, McMaster University, Hamilton, ON, L8S 4K1, Can.  
SOURCE: Experimental and Clinical Psychopharmacology (1996), 4(3), 258-263  
PUBLISHER: CODEN: ECLPES; ISSN: 1064-1297  
DOCUMENT TYPE: American Psychological Association  
LANGUAGE: Journal English

AB The results of 3 expts. demonstrated that (a) 20 mg/kg **ibogaine** (but not 10 mg/kg), administered 30 min before morphine, attenuates the development of tolerance to the **analgesic** effect of morphine in rats; (b) this 20 mg/kg dose of **ibogaine**, if administered 5 h before morphine, has no effect on tolerance development; and (c) a high dose of **ibogaine** (40 mg/kg), administered 24 h before morphine, does not affect **analgesic** tolerance (despite reports that this dose of **ibogaine**, administered 1 day before morphine, modulates the neurochem. and reinforcing effect of the opiate. The findings are discussed in the context of suggestions that **ibogaine** be evaluated as a treatment for opiate dependence, and recent research indicating that **ibogaine** is an N-methyl-D-aspartate antagonist.

L3 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:871276 CAPLUS  
DOCUMENT NUMBER: 123:275915  
TITLE: High affinity ibogaine binding to a mu opioid agonist site  
AUTHOR(S) : Codd, Ellen E.  
CORPORATE SOURCE: Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA  
SOURCE: Life Sciences (1995), 57(20), PL315-PL320  
PUBLISHER: CODEN: LIFSAK; ISSN: 0024-3205  
DOCUMENT TYPE: Elsevier  
LANGUAGE: Journal English

AB The naturally occurring indole alkaloid **ibogaine** is of interest because of its reported ability to block drug-seeking behavior for extended periods. The compound also potentiates morphine-induced **analgesia** in mice and reduces certain naltrexone-precipitated withdrawal signs in morphine-dependent rats. Although these results might suggest **ibogaine** interaction with opioid receptors, previous receptor binding studies (Brain Res. 571:242-247, 1980) found that **ibogaine** had a Ki value of only 2  $\mu$ M for the kappa opioid receptor and was virtually inactive in blocking mu and delta receptor binding (Ki > 100  $\mu$ M). The present investigation of **ibogaine** interaction with the mu opioid receptor from mouse forebrain labeled with [3H]-naloxone, however, yielded significantly more potent mu opioid Ki values. LIGAND anal. indicated that the data were best fit by a two site binding model, with Ki values of about 130 nM and 4  $\mu$ M, reflecting **ibogaine** recognition of different agonist affinity states of the receptor. Inclusion of 100 mM NaCl in the assay to induce the agonist low affinity state of the receptor, reduced **ibogaine**'s inhibition of [3H]-naloxone binding. These results suggest that **ibogaine** is an agonist at the mu opioid receptor with a Ki value of about 130 nM, potentially explaining **ibogaine**'s antinociceptive effects as well as its reported reduction of opioid withdrawal symptoms and attenuation of drug seeking behavior.

L3 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:749395 CAPLUS  
DOCUMENT NUMBER: 123:199189  
TITLE: Medicinal chemical studies of anti-inflammatory and analgesic natural products  
AUTHOR(S) : Shen, Tsung-Ying  
CORPORATE SOURCE: Chem. Dep., Univ. Virginia, Charlottesville, VA, 22903, USA  
SOURCE: Journal of the Chinese Chemical Society (Taipei)

(1995), 42(4), 617-21  
CODEN: JCCTAC; ISSN: 0009-4536

PUBLISHER: Chinese Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A symposium, following the discovery of salicylates and its conversion to aspirin, natural products research has provided many promising leads for further modification as anti-inflammatory and **analgesic** agents. Recent studies have focused on biosynthesis inhibitors of eicosanoids and receptor antagonists of the platelet activating factor, including a new class of dual functional inhibitors derived from neolignans. The highly potent **analgesic** alkaloid epibatidine from the frog skin has been synthesized and recharacterized as a very strong acetylcholine nicotinic receptor agonist. Some novel epibatidine analogs have shown promise as potential central nervous system drugs and research probes for clarifying the anti-addictive property of the African alkaloid **ibogaine**.

L3 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:97857 CAPLUS  
DOCUMENT NUMBER: 78:97857  
TITLE: Acyl derivatives of 10-methoxyibogamine  
INVENTOR(S): Epstein, Joseph William; Goldman, Leon  
PATENT ASSIGNEE(S): American Cyanamid Co.  
SOURCE: U.S., 3 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 3715361	A	19730206	US 1971-187895	19711008
PRIORITY APPN. INFO.:			US 1971-187895	A 19711008

GI For diagram(s), see printed CA Issue.  
AB The title compds. (I, R, = H, CHO; R1 = Ac, CHO, H; R2 = Ac, H) were prepared by acylation of **ibogaine** (I, R = R1 = R2 = H) with mixts. of DMF-POCl<sub>3</sub>, Me<sub>2</sub>N(:CHCl)Cl-CHCl<sub>3</sub>, s-triazine-CF<sub>3</sub>CO<sub>2</sub>H, or AcOH-Ac<sub>2</sub>O-BF<sub>3</sub>. I showed **analgetic** and antiinflammatory activity in rats with doses of 50 to 250 mg/kg.

*not the same compound*

L3 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1958:27271 CAPLUS  
DOCUMENT NUMBER: 52:27271  
ORIGINAL REFERENCE NO.: 52:4935h-i  
TITLE: Analgesic compositions  
INVENTOR(S): Schneider, Jurg A.  
PATENT ASSIGNEE(S): Ciba Pharmaceutical Products, Inc.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 2817623		19571224	US	

AB Tabernanthine and **ibogaine** potentiate **analgesics**, e.g., **morphine**, codeine, dihydromorphinone, dihydromethylmorphinone, pantopon, ethylmorphine, ketobemidon, meperidine, dihydrocodeinone, dihydromorphine, dihydrodeoxymorphine, dihydrodeoxycodeine, DL-3-methoxy-N-methylmorphinan, and DL-3-hydroxy-N-methylmorphinan. The ratio of the indole alkaloid to the **analgesic** component is 0.5-20:1. The ingredients may be incorporated in injectable solns., tablets, or capsules.

L3 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1956:91229 CAPLUS

DOCUMENT NUMBER: 50:91229  
ORIGINAL REFERENCE NO.: 50:17154b-d  
TITLE: Potentiating action of **ibogaine** (Bogadin TM)  
on morphine **analgesia**  
AUTHOR(S): Schneider, J. A.; McArthur, Marie  
CORPORATE SOURCE: Ciba Inc., Summit, NJ  
SOURCE: Experientia (1956), 12, 323-4  
CODEN: EXPEAM; ISSN: 0014-4754  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB In white mice ibogaine-HCl (I) has a marked potentiating effect on morphine (II), ketobemidone, codeine, and Demerol, but not on aminopyrine. The most effective combination with II was 3 mg. with 24 mg. I. The toxicity of I-II combinations is greater than for either alone; the L.D.50 for equal amts. appears to be about 70 mg. of each.